BioInvent

287 articles about BioInvent

• Change in the Number of Shares and Votes in BioInvent International AB

  7/29/2022

  BioInvent International AB announced that the company's total number of shares as per July 29, 2022 amounts to 64,967,884 shares, corresponding to an equal number of votes.

• Resolutions at the Extraordinary General Meeting in BioInvent on July 12, 2022

  7/12/2022

  BioInvent International today resolved to elect Natalie Berner and Nanna Luneborg as new Board members.

• BioInvent and Transgene Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA(R)

  6/28/2022

  BioInvent International AB and Transgene announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the oncolytic virus BT-001 in combination with MSD's anti-PD-1 therapy KEYTRUDA® in a Phase 1/2a clinical trial for the treatment of patients with solid tumors.

• Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA®

  6/28/2022

  Transgene and BioInvent International AB announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the oncolytic virus BT-001 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® in a Phase I/IIa clinical trial for the treatment of patients with solid tumors.

• Transgene and BioInvent Announce Positive Progress for BT-001

  6/27/2022

  Transgene and BioInvent International AB jointly announced positive progress and safety data of the ongoing Phase I/IIa trial evaluating BT-001 in patients with solid tumors, including melanoma.

• 

  ADC Space Continues to Thrive with Four More Companies Linking Up

  6/16/2022

  This week sees Exelixis, BioInvent, ImmunoGen and Oxford BioTherapeutics coming together to develop antibody-based therapies for cancer.

• Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

  6/16/2022

  Exelixis, Inc. and BioInvent International AB announced that the companies have entered into an option and license agreement focused on the identification and development of novel antibodies for use in IO therapeutics.

• Natalie Berner of Redmile and Nanna Lüneborg of Forbion proposed as New Board Members of BioInvent

  6/16/2022

  BioInvent International AB announces on behalf of the nomination committee, the proposal to elect Natalie Berner and Nanna Lüneborg as new Board members, at the Extraordinary General Meeting on July 12, 2022.

• BioInvent's BI-1206 to Advance into Expansion Stage of Phase 1/2a Study in NHL after a Productive End-of-Phase 1 FDA Meeting

  5/3/2022

  BioInvent International AB announces its novel anti-FcyRIIB antibody BI-1206 is progressing into the expansion phase of a Phase 1/2a trial for non-Hodgkin's lymphoma, following a positive End-of-Phase 1 meeting with the US FDA.

• BioInvent Receives Milestone Payment from Bayer/Hope Medicine Licensing Agreement

  4/28/2022

  BioInvent International AB announces that it receives a milestone payment following clinical progression of an out-licensed antibody.

• Resolutions at BioInvent's Annual General Meeting 2022

  4/28/2022

  The Annual General Meeting of BioInvent International AB resolved to re-elect the Board members Kristoffer Bissessar, Dharminder Chahal, Thomas Hecht, Leonard Kruimer, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program.

• BioInvent International AB: Interim Report January-March 2022

  4/27/2022

  The exciting translational data presented on BI-1808 at AACR clearly show why we are so enthusiastic about our ongoing clinical studies in solid tumors.

• BioInvent International AB publishes Annual Report 2021

  4/7/2022

  BioInvent International AB announced that the Annual Report for 2021 has been published.

• Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022

  3/9/2022

  Transgene and BioInvent International AB jointly announce that an abstract reporting preclinical studies of BT-001, a novel oncolytic virus, has been selected for a poster presentation at the American Association for Cancer Research Annual Meeting 2022.

• BioInvent AACR Data Boost Prospects for BI-1808

  3/8/2022

  BioInvent International AB announces that data regarding the anti-TNFR2 drug candidate BI-1808, currently in clinical development, will be presented at the forthcoming annual meeting of the American Association for Cancer Research in April 2022.

• BioInvent and Transgene Announce Poster Presentation on BT-001, a Novel Antibody-Encoding Oncolytic Virus, at AACR 2022

  3/8/2022

  BioInvent International AB and Transgene jointly announce that an abstract reporting preclinical studies of BT-001, a novel oncolytic virus, has been selected for a poster presentation at the American Association for Cancer Research Annual Meeting 2022.

• BioInvent's BI-1607 to Extend Reach of Anti-FcyRIIB Approach to Breast Cancer

  3/8/2022

  BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces that the company will be presenting the first data for BI-1607 at the forthcoming annual meeting of the American Association for Cancer Research in April 2022.

• BioInvent International AB (publ) Year-End Report January 1 - December 31, 2021

  2/23/2022

  The past year was very exciting for BioInvent. Two of our clinical trials provided highly encouraging results in 2021 at the same time as we expanded our pipeline of clinical programs with the initiation of two additional programs and the submission of one clinical trial application, more than doubling the portfolio.

• Invitation to Presentation of BioInvent's Year-end Report 2021

  2/18/2022

  Lund, Sweden, February 18, 2022 - BioInvent International AB invites to a presentation of the Year-end report 2021 and a telephone conference with CEO Martin Welschof.

• BioInvent & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

  1/20/2022

  BioInvent International AB and Transgene jointly announce the publication of extensive preclinical proof-of-concept data for BT-001 in the Journal for ImmunoTherapy of Cancer.